Subclinical cardiotoxicity in childhood cancer survivors exposed to very low dose anthracycline therapy. Issue 1 (30th August 2014)
- Record Type:
- Journal Article
- Title:
- Subclinical cardiotoxicity in childhood cancer survivors exposed to very low dose anthracycline therapy. Issue 1 (30th August 2014)
- Main Title:
- Subclinical cardiotoxicity in childhood cancer survivors exposed to very low dose anthracycline therapy
- Authors:
- Leger, Kasey
Slone, Tamra
Lemler, Matthew
Leonard, David
Cochran, Cindy
Bowman, W. Paul
Bashore, Lisa
Winick, Naomi - Abstract:
- <abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="pbc25206-sec-0001" sec-type="section"> <title>Background</title> <p>Subclinical cardiotoxicity occurs in childhood cancer survivors following moderate and high anthracycline doses. However, less is known about the subclinical changes in left ventricular (LV) structure that occur after very low anthracycline doses of ≤100 mg/m<sup>2</sup>. This study was designed to assess LV function and key structural parameters following very low doses of anthracycline.</p> </sec> <sec id="pbc25206-sec-0002" sec-type="section"> <title>Procedure</title> <p>Conventional 2‐dimensional echocardiograms with Doppler were obtained in 91 survivors of childhood cancer exposed to ≤100 mg/m<sup>2</sup>, an average of 9.8 years from diagnosis. LV structural measurements were converted into Z‐scores. The Z‐score distributions were compared to those of the normal population. Diastolic and systolic function were quantified.</p> </sec> <sec id="pbc25206-sec-0003" sec-type="section"> <title>Results</title> <p>The cohort demonstrated a decreased posterior wall thickness (mean Z‐score −1.01) and mildly decreased LV end diastolic (mean Z‐score −0.85) and systolic (mean Z‐score −0.84) dimensions compared to the normal population (<italic>P</italic> &lt; 0.001). Further, 28% of patients (n = 25) had abnormal LV posterior wall thickness, ≥2 standard deviations below the mean (Z‐score ≤ −2). There were no patients with<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="pbc25206-sec-0001" sec-type="section"> <title>Background</title> <p>Subclinical cardiotoxicity occurs in childhood cancer survivors following moderate and high anthracycline doses. However, less is known about the subclinical changes in left ventricular (LV) structure that occur after very low anthracycline doses of ≤100 mg/m<sup>2</sup>. This study was designed to assess LV function and key structural parameters following very low doses of anthracycline.</p> </sec> <sec id="pbc25206-sec-0002" sec-type="section"> <title>Procedure</title> <p>Conventional 2‐dimensional echocardiograms with Doppler were obtained in 91 survivors of childhood cancer exposed to ≤100 mg/m<sup>2</sup>, an average of 9.8 years from diagnosis. LV structural measurements were converted into Z‐scores. The Z‐score distributions were compared to those of the normal population. Diastolic and systolic function were quantified.</p> </sec> <sec id="pbc25206-sec-0003" sec-type="section"> <title>Results</title> <p>The cohort demonstrated a decreased posterior wall thickness (mean Z‐score −1.01) and mildly decreased LV end diastolic (mean Z‐score −0.85) and systolic (mean Z‐score −0.84) dimensions compared to the normal population (<italic>P</italic> &lt; 0.001). Further, 28% of patients (n = 25) had abnormal LV posterior wall thickness, ≥2 standard deviations below the mean (Z‐score ≤ −2). There were no patients with diastolic dysfunction or symptomatic systolic dysfunction, however four patients demonstrated abnormal SF ≤ 28%.</p> </sec> <sec id="pbc25206-sec-0004" sec-type="section"> <title>Conclusions</title> <p>A significant proportion of patients exposed to very low doses of anthracycline demonstrate subclinical abnormalities in LV structure, despite the absence of radiation or other risk factors. While we cannot say whether these structural changes will result in clinically significant cardiac disease, the reported progressive nature of these findings raises concern that there may truly be no safe dose of anthracycline. Pediatr Blood Cancer 2015;62:123–127. © 2014 Wiley Periodicals, Inc.</p> </sec> </abstract> … (more)
- Is Part Of:
- Pediatric blood & cancer. Volume 62:Issue 1(2015:Jan.)
- Journal:
- Pediatric blood & cancer
- Issue:
- Volume 62:Issue 1(2015:Jan.)
- Issue Display:
- Volume 62, Issue 1 (2015)
- Year:
- 2015
- Volume:
- 62
- Issue:
- 1
- Issue Sort Value:
- 2015-0062-0001-0000
- Page Start:
- 123
- Page End:
- 127
- Publication Date:
- 2014-08-30
- Subjects:
- Tumors in children -- Periodicals
Blood -- Diseases -- Periodicals
Cancer in children -- Periodicals
618.92 - Journal URLs:
- http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1545-5017 ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1002/pbc.25206 ↗
- Languages:
- English
- ISSNs:
- 1545-5009
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 6417.533500
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 3588.xml